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Endometriosis is a common gynecological disorder affecting 6%–10% of women of 
reproductive age and 35%–50% of women experiencing chronic pelvic pain and/or infertility. 
The most widely accepted mechanism of this disease is the entry of endometrial cell aggregates 
into the peritoneal cavity via the fallopian tubes in a process known as retrograde menstruation. 
These endometrial fragments attach and invade the peritoneal surfaces, eventually forming 
lesions. Primates are the only species that naturally develop endometriosis, however due to the 
expense and difficulty of working with these species, models based in laboratory species have 
been developed. Using a mouse transplantation model of endometriosis that mimics the 
progression of the disease in humans, we investigated the effects of di (2-ethylhexyl) phthalate, a 
known endocrine disruptor, on establishment of endometriotic lesions and neuroinflammation. 
To accomplish this, we validated the optimal estrogen dose for supplementation and monitored 
lesion progression over time following transplantation surgery. We then determined if mice with 
endometriotic lesions show signs of pain or discomfort using a behavioral assay. We also 
examined whether there is a genetic impact on the incidence and progression of endometriosis in 
our mouse model by comparing two different strains of mice. Finally, we determined the effects 
of di (2-ethylhexyl) phthalate (DEHP) on lesion development in our mouse model. Our main 
findings are that, 1) supplementing ovariectomized mice with 100 ng or 1 µg of 17β-estradiol 
every 4 days is not sufficient for the long term maintenance of endometriotic lesions. However 
supplementation with estradiol valerate resulted in a higher incidence of endometriotic lesions 
containing glands; 2) mice with endometriotic lesions show signs of  discomfort or pain in 
association with induction of  endometriosis; 3) the presence of endometriotic lesions resulted in 
increased numbers of  activated microglia in the hippocampus of the brain; 4) C57BL/6 mice are 
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a superior mouse strain for use in  a mouse model of endometriosis; and 5) treatment of  mice 
with 30 mg/kg/day or 60 mg/kg/day DEHP resulted in increased incidence and size of lesions 
and increased cell proliferation in endometriotic lesions. These results show that we have 
validated a mouse model for endometriosis that can be used to investigate how the presence of 
these lesions leads to increased neuroinflammation and visceral pain and how exposure to 
environmental factors such as phthalates may promote establishment and progression of this 
disease.  The findings of these studies are highly relevant to understanding the mechanisms of 
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CHAPTER 1: LITERATURE REVIEW 
ENDOMETRIOSIS 
            Endometriosis is a common benign gynecological disorder affecting 6%–10% of women 
of reproductive age and up to 35%–50% of women experiencing chronic pelvic pain and/or 
infertility.1 The most widely accepted mechanism of this disease is the entry of endometrial cell 
aggregates into the peritoneal cavity during menstruation via the fallopian tubes, a process 
known as retrograde menstruation, where these endometrial fragments attach and invade into the 
peritoneal surfaces and grow into lesions.2 The endometriotic lesions are made up of endometrial 
glands and stroma; this tissue has been known to attach to the ovary, intestines, bladder, and 
peritoneal wall as well as on the exterior surface of the uterus and recto-vaginal pouch3. The 
diagnosis and removal of the lesions is only possible through laparoscopy making diagnosis very 
difficult and often delayed due to high expense and invasiveness.4 Due to the fact that 
development of endometriotic lesions decreases after menopause or ovariectomy, it can be 
concluded that endometriosis is an estrogen-dependent disease.5 The disease can be induced by 
improper antegrade menstruation which can be caused by a defect in the reproductive tract. The 
progression of the disease can be aided by immune system failure or dysregulation in the 
peritoneal cavity and an increase in environmental estrogen levels (Figure 1).6,7 Nutrition and 
genetics also play a role in the incidence of the disease, making it difficult to pinpoint the 
etiology of the disease.8 
ANIMAL MODELS OF ENDOMETRIOSIS  
Due to the nature of the disease, only primates can naturally develop endometriosis since 
they are the only species that menstruate. Common mammalian laboratory models such as mice, 
rats or rabbits do not menstruate, so endometriosis must be artificially induced in these species. 
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Since research with primates is very difficult and costly, models have been made in other species 
to be able to study the disease, thus there are models with spontaneous development of the 
disease as well as models where the disease is induced artificially.9  
SPONTANEOUS MODELS OF ENDOMETRIOSIS 
  The rhesus macaque (Macaca mulatta) and the baboon (Papio anubis) are the most 
common models of spontaneous endometriosis because the disease develops naturally in these 
species. Endometriosis is more likely to occur in older animals,10 so the animals need to be 
housed for many years before spontaneous development of the disease occurs. This can be costly 
and time-consuming. The endometriotic lesions formed in non-human primates are identical to 
those found in humans.10–13 One problem with these models is that endometriosis occurs 
naturally only in a small proportion of the captive breeding populations of both rhesus macaques 
and baboons, resulting in small sample sizes that are not conducive to scientific research.14–16 
There is also trouble diagnosing the disease in these animals because there is no way for the 
animals to communicate that they are in distress. The only ways the disease can be detected in 
these animals is by biopsy, necropsy or laparotomy.9,11 These complications contribute to a 
decrease in the use of the spontaneous induction model because it is less than ideal for 
experimental setup.  
AUTO-TRANSPLANTATION MODELS OF ENDOMETRIOSIS 
 Although spontaneous models are possible with non-human primates induction of 
endometriosis is often done to ensure a diseased population to study. Autotranplantation of 
menstrual endometrial tissue collected from baboons is used to inoculate the peritoneal cavity 
with endometriosis. Multiple surgeries can be done to ensure implantation of endometriosis and 
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progression of the disease can be monitored by laparoscopic imaging.17–20 Due to the ability to 
easily visualize the lesions without removal allows for detailed observations over a long time 
span with monitoring done 16 months post-autotranplantation of tissue. The lesions collected 
from this model are histologically and morphologically identical to endometriotic lesions found 
in women.13,17,19,21 This model is a great tool that has answered many questions about 
endometriosis. The model has been validated to show that baboons with endometriosis respond 
to estradiol and develop progesterone resistance in the eutopic endometrium similarly to women 
with endometriosis.17,19,22,23 This model has been used to determine the effects of aromatase 
inhibitors on lesions development and growth as well as determining a large number of 
differences in gene expression in the lesions compared to a patient matched endometrium 
sample.18,21,22,24 Mapping aromatase expression and steroid receptor populations in endometriotic 
lesions was also accomplished with this model.24 A drawback from this model is still the 
increased expense of working with non-human primates as well as the increased surgical 
expertise and equipment.  
Autotransplantation models in mice involve the removal of uterine tissue from a donor 
animal and either harvesting tissue punches, minced tissue, or collecting fragments for 
transplantation into a recipient animal. This can be done by injecting minced tissue suspended in 
phosphate buffered saline into the peritoneal cavity of the recipient,25 suturing tissue punches to 
the intestinal mesentery,26 or suturing tissue fragments to various sites on the peritoneum.27 Each 
of these models has resulted in successful induction of endometriosis. The transplantation 
method allows for rapid development of the disease, synchronized control of the time course of 
the disease and easy repeatability. These models are now used frequently and have led to 
significant progress in understanding the disease.25,28 This model can also be used with various 
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strains and genetic knockouts of mice to investigate specific signaling pathways. For example, 
Burns et al. have used this model with estrogen receptor α (ERα) and estrogen receptor β (ERβ) 
knockout mice to determine the effects of estrogen signaling in the development of lesions. The 
ERα knockout tissue transplanted into wild type mice resulted in a decreased incidence of 
endometriotic lesions demonstrating that ERα signaling is important for lesion establishment and 
development.25 These various mouse models are used frequently and have led to increased 
understanding of  the disease.9,25,28–30 
NERVE FIBERS AND ENDOMETRIOSIS  
 
Common symptoms of endometriosis are pain, dysmenorrhea, and dyspareunia.31,32 
Investigation of what causes these symptoms has led to studying the development and 
distribution of nerve fibers in and around endometriotic lesions. Following the establishment of 
endometriotic lesions there is substantial innervation that occurs in the affected areas.33 Studies 
have shown that women without endometriosis have substantially fewer sensory C nerve fibers 
present in the functional layer of the endometrium when compared to women with 
endometriosis.34,35 A variety of markers have been used to determine what these nerve fibers are 
expressing, and results have shown that there is a marked increase in several proteins normally 
present in the uterine tissue of women with endometriosis including protein gene product 9.5 
(PGP9.5), neuropeptide Y (NPY), and vasoactive intestinal polypeptide (VIP). PGP9.5 is a 
marker used to identify c fibers which are responsible for pain that has been described as “dull” 
or “pressing”.34,36 Autotransplantation of uterine tissues in rats showed that PGP9.5 expression 
was present throughout and around the endometriotic lesions mimicking a similar 
immunostaining in eutopic uterine tissue from the same animal.37 NPY is expressed in the 
nervous system of all mammals and an increased expression has been observed in models of 
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chronic pain.38 VIP expression has been known to increase after nerve injury and to exacerbate 
perceptions of pain.39 These results showing that women with endometriosis have more nerve 
fibers in their eutopic endometrium increasing the probability for experiencing pain with 
menstruation. This has been confirmed in animal models of endometriosis as well as in 
endometriotic lesion tissue obtained from women.37 
ENDOCRINE DISRUPTING CHEMICALS 
Endocrine disrupting chemicals (EDCs) are a group of chemicals that mimic or interfere 
with the body’s natural endocrine signals. These chemicals act on various endocrine receptors 
and enzymatic pathways and have effects on steroidogenesis.40 These chemicals can have severe 
adverse effects on the body in higher amounts and contact and consumption needs to be 
monitored and avoided when possible. EDCs are ubiquitous in our environment. Humans and 
animals are under almost constant exposure throughout an average day of activities and work. 
Although these chemicals are ubiquitous, exposure routes and levels will vary based on 
geographical location, occupation, lifestyle, and diet. There are many different types of EDCs to 
which humans are exposed. Some of the more common groups are phthalates, phytoestrogens, 
perfluorinated chemicals, organophosphate pesticides, and heavy metals.41–46 One complication 
with studying EDCs is that they tend to act in a biphasic manner or follow a non-monotonic dose 
response in the body.47 Many studies have shown adverse effects with EDCs at lower doses and 
no adverse response at higher doses.48–50 Adverse effects at small doses makes it very easy for 
EDCs to act and cause a detrimental response with minimal exposure.48  
 
PHTHALATES  
 Phthalates are a group of colorless, odorless EDCs that are added to hard plastics to make 
a more malleable product. Over 470 million pounds of phthalates are produced in the United 
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States each year. There are many phthalates that contribute to this production, including di(2-
ethylhexyl) phthalate (DEHP), di-n-butyl phthalate (DBP), diethyl phthalate (DEP), di-n-
octylphthalate (DNOP), and diisononyl phthalate (DINP).51–53 Phthalates are quickly 
metabolized in the body and the metabolites of phthalates have been detected regularly in the 
urine, blood, and breast milk of humans at various levels. Phthalate metabolites are thought to be 
more toxic than the parent phthalate, due to their increased half-life in the body.54,55  
Phthalates are found in many common household items such as shower curtains, children’s toys, 
and food packing.52,56–58 Phthalates are also often also added to personal care products such as 
lotions, shampoos, nail polish, and cosmetics.59–61 The addition of phthalates to these commonly 
used items leads to constant daily exposure in humans, and this has been confirmed by the 
presence of phthalate metabolites in the urine.55,62,63 Phthalates leach from plastics into the 
environment when the plastic containing phthalates goes through a change in temperature, 
normal use/handling or degradation of the item due to sun exposure.57,64 Humans are constantly 
exposed to these phthalates through regular use of any of these items, through exposure from 
eating and drinking out of plastic containers made with phthalates, receiving treatments with 
medical tubing, and breathing in dust that is contaminated with phthalates.  
DI (2-ETHYLHEXYL) PHTHALATE (DEHP) 
 
 DEHP is a long-chain phthalate that, in combination with DINP, makes up approximately 
75% of the phthalates produced.65,66 DEHP is a known EDC with reported negative effects on 
fertility and pregnancy success in lab animals and humans.67,68 Many studies have investigated 
the effects of DEHP on reproductive outcomes, as well as malformations and dysfunction in the 
reproductive tracts of both male and female lab animal species.69–78 In addition to the effects 
reported in reproductive outcome studies, DEHP has been shown to have negative impacts on the 
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lungs, kidney, immune system, brain, and liver, including changes in morphology, normal 
function of organs, and behavior, memory and learning in mice.79–81 DEHP is rapidly 
metabolized into mono-(2-ethylhexyl) phthalate, MEHP, upon entering the body. MEHP is also 
quickly oxidized, resulting in metabolites that have longer half-lives than DEHP or MEHP.55 
DEHP and its metabolites are excreted in the urine in a relatively short amount of time, but, with 
constant exposure from the environment, these metabolites can accumulate in the body and cause 
damage. The mechanisms by which DEHP and its metabolites cause damage in these 
physiological systems are unclear , although there have been several  studies showing that 




 Inflammation is the body’s response to insults such as exposure to heat, cold, and 
infection or trauma such as ischemia, abrasion or other forms of physical harm.83,84 The purpose 
of inflammation is to direct immune cells to the site of the insult or trauma and to remedy the 
situation through the clearing of cellular debris and possible micro-organisms present.85–87 This 
is accomplished by immune cells; these cells are important for signaling changes in blood vessels 
and for performing phagocytosis. The blood vessels are dilated to allow an increased blood 
supply to the affected area; there is also an increase in permeability of the vessels to allow 
extracellular fluid to collect in the damaged area. Immune cells will accumulate in this fluid and 
phagocytosis begins. When phagocytosis is activated phagocytes locate and engulf the targeted 
debris for digestion.88 The common immune cells involved in phagocytosis are neutrophils, 
monocytes, and macrophages.83 These cells are also important for secreting cytokines that are 
crucial for modulating the immune response. Once the cellular debris is removed the body is able 
to re-establish homeostasis. Chronic inflammation occurs if the immune response is not 
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sufficient to eliminate whatever is causing the acute inflammation.86 This chronic inflammation 
can lead to a persistent accumulation of immune cells that are secreting pro-inflammatory 
cytokines resulting in increased inflammatory response and positive feedback loop of continued 
spread of inflammation.89  
ENDOMETRIOSIS ASSOCIATED INFLAMMATION  
  Endometriosis is considered a chronic inflammatory disease. Women with endometriosis 
have increased numbers of peritoneal macrophages and levels of pro-inflammatory cytokines in 
the peritoneal fluid.7,90–93 The higher levels of cytokines seen in women with endometriosis are 
due to cells within the endometriotic lesions and peritoneal macrophages which secrete tumor 
necrosis factor α (TNFα), transforming growth factor-β (TGFβ), and interleukin 6 (IL-6).12,94 The 
release of these pro-inflammatory and pro-fibrotic cytokines in response to the presence of 
foreign tissue induces an innate immune response in the peritoneal cavity.12,94,95 However, the 
phagocytes in women with endometriosis have been shown to have decreased phagocytic 
capabilities in dealing with the foreign endometrial tissue in the peritoneal cavity and the triggers 
for inflammation remain.7,90,91,95,96 Due to the inability of the body to clear the endometriotic 
tissue, chronic inflammation will develop and continue to occur in the peritoneal cavity which 
can spread and induce inflammatory responses in the brain and nervous system.30,97–99 There are 
multiple pathways by which peritoneal inflammation can signal to the brain. For example, 
immune cells can act on the vagal and spinal afferent fibers that send neuronal signals to the 
brain. In addition, the pro-inflammatory cytokines that are secreted by the immune cells in the 






Microglia are the resident immune cells of the central nervous system (CNS). Under 
normal conditions these cells have a ramified morphology, with long outstretched processes to 
aid in the constant scanning of the brain. Damaged or dead neurons, oxidative stress, and 
pathogen presence in the brain are triggers for activation of microglia.102–105 Inflammation in the 
brain and spinal cord is characterized by the activation of these cells.103,106,107 The activation of 
these cells results in morphological changes and triggers release of pro-inflammatory 
cytokines.103–105Activated microglia and astrocytes become hypertrophic and retract their 
processes to become highly motile throughout the brain in order to locate and phagocytose the 
initial trigger in the affected areas (Figure 3).108,109 Once the damaged cells and debris are 
cleared, microglia aid in repair and restructuring of the neuronal circuits.108 Failure to properly 
remedy the situation leads to chronic activation of the microglia and astrocytes. Chronic 
neuroinflammation can also occur when there is chronic pro-inflammatory signaling from other 
areas of the body such as the peritoneal cavity to the brain.104,110,111 With prolonged 
inflammation in the brain the microglia have been shown to aid in neurodegeneration through 
phagocytosis of healthy neurons, secretion of reactive oxygen species and desensitization to 
normal stimuli allowing for the buildup of plaque and debris. This process of chronic 
neuroinflammation has been linked with many neurodegenerative diseases including Parkinson’s 

























Figure 1. Initiation of endometriosis. Endometriosis initiated by 
retrograde menstruation and implantation of endometrial tissue is aided by 






















Figure 2. Signaling for neuroinflammation. There are 
multiple pathways in which inflammation from the peritoneal 






















Figure 3. Activation of microglia. Microglia can be activated 
by multiple insults and proinflammatory cytokines. Once 
activated, microglia secrete cytotoxins that damage neurons and 
other microglia.114  
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CHAPTER 2: VALIDATION OF THE MOUSE ENDOMETRIOSIS MODEL 
INTRODUCTION 
 Studying endometriosis using animal models is challenging because the disease occurs 
naturally only in primates. This is due to the fact that they are the only species that shed their 
endometrium through menstruation. In order to be able to better understand this disease, several 
models have been developed to mimic endometriosis in rodents. One commonly used model 
involves transplantation of pregnant mare serum gonadotropin (PMSG)-primed donor uterine 
tissue that has been minced finely into the peritoneal cavity of ovariectomized recipient mice. 
While this model has shown success, there are a number of variables that can affect the outcome 
of these methods. First, there is no set standard dose of estradiol (E) supplementation for this 
model, so different studies have used varying levels of E supplementation.5,27,28,115 Estradiol is 
important for proper function of the female reproductive tract, such as proliferation and function 
of the endometrium, follicle development, and induction of hormone receptors in the 
reproductive tract.116,117, For example, ovariectomized mice that lack sufficient doses of 
supplemental E are often found to have small uteri. The level of E supplementation is an 
important factor for studying endometriosis because it is a hormone- dependent disease that 
responds to hormone signaling similarly to the uterus. Finding the appropriate level of E 
supplementation is important because insufficient E would not have the same supportive effect 
on the development of endometriotic lesions resulting in decreased incidence or lack of lesions.  
The goal of this study was to validate the transplantation mouse model used in our lab by 
determining the optimal E dose for supplementation and by following lesion progression over 
time. Endometriotic lesions in women are defined as the presence of endometrial tissue outside 
of the uterus and consist of both endometrial stromal cells and endometrial glands. Endometriotic 
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lesions in women are also well vascularized and this has been confirmed by the presence of 
numerous blood vessels in the lesions. As part of the validation of our model, we examined 
lesions collected from our mice to confirm the presence of endometrial components and the 
vascular supply in the mouse lesions. We also used a behavioral test as a way to monitor 
discomfort and/or pain in the mice with lesions, as pain is a common symptom in women with 
endometriosis. We chose to use a burrowing assay protocol because it is a noninvasive activity 
test that has a good correlation with the level of visceral pain.118–120  
MATERIALS AND METHODS  
Endometriosis Pilot Study  
Animal experiments were approved by the University of Illinois Institutional Animal 
Care and Use Committee and followed the guidelines of the National Institutes of Health 
standards for the use and care of animals. Female CD-1 mice were purchased from Charles 
River. Mice were kept in a light and temperature-controlled animal facility (12 h daylight: 12 h 
dark) and were provided with Teklad diet 7013 and water ad libitum. 
Female recipient mice (Table 1) (6-8 weeks old) were anesthetized with an 
intraperitoneal (i.p.) injection of Ketamine/Xylazine (87 mg/kg; 15 mg/kg). A 1 cm dorsal 
midline incision was made through the skin, and then two 0.5 cm incisions were made through 
the muscle lateral to the midline. The ovaries were located and removed by clamping the ovarian 
stalk and cutting the ovary tissue off, then ligating the oviduct to prevent excess bleeding. 
Following ligation sterile absorbable suture was used to close the muscle incisions. Skin 
incisions were closed with wound clips and the mouse was allowed to recover on a warming pad 
until it regained consciousness. Buprenorphine (0.05 mg/kg, subcutaneously) was used as an 
analgesic to minimize pain and discomfort and was administered one hour before surgery as well 
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as 6-10 hours after the initial dose to reduce discomfort and pain. Animals were monitored daily 
and wound clips were removed 10 days post-surgery. 
Syngeneic female mice were used as a source of donor tissue. The donor mice were 
primed with 5 IU of pregnant mare serum gonadotropin (PMSG; i.p.) 48 hours prior to 
harvesting of the uterus in order to stimulate the growth of the endometrial tissue.  Uterine 
tissues were collected from donor mice, chopped into small pieces (<0.5 mm), washed in sterile 
phosphate buffered saline (PBS), and suspended in 1.0 ml PBS at RT. Recipient mice were 
anesthetized 14 days after ovariectomy using the same cocktail as described previously 
(Ketamine/Xylazine (87 mg/kg; 15 mg/kg; i.p.) A 0.5 cm dorsolateral incision was made and 0.5 
ml of the uterine fragment suspension was gently injected into the peritoneal cavity of the 
recipient mouse. We divided the uterine tissue from one donor mouse between two recipient 
mice. After the introduction of the tissue into the peritoneal cavity, closure of the muscle layer 
was accomplished with sterile absorbable suture and skin incisions with wound clips. Recipient 
mice were given buprenorphine (0.05 mg/kg) 1 hour prior to administering anesthesia and 6-10 
hours after the initial dose to reduce discomfort and pain from surgery.  
The recipient mice were injected subcutaneously with the first dose of E (100 ng/mouse) 
in corn oil 4 days before the transplantation surgery, and injections were continued every 4 days 
until euthanasia to help maintain disease progression. Recipient mice were euthanized at 4, 8 and 
16 days after tissue transplantation and transcardially perfused with sterile PBS. The number, 
location, and sizes of endometriotic lesions were recorded and lesions collected into 10% neutral 
buffered formalin. Uterine, liver, spine and brain tissue were harvested for histological analysis 
and RNA processing. In addition, we collected digesta and fecal samples from the cecum, colon, 
and ileum of the small intestine.  
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Endometriosis Study #2 
The second study differed from our first study in that the recipient mice (Table 2) were 
injected subcutaneously with a higher dose of estradiol (1 µg/mouse). The first injection was 
given 4 days before the transplantation surgery, and subsequent injections were continued every 
4 days until euthanasia to help maintain disease progression. Recipients were euthanized at 4, 8, 
and 16 days after tissue transplantation and transcardially perfused with sterile PBS. The 
number, location, and sizes of endometriotic lesions were recorded, and lesions were collected 
into 10% neutral buffered formalin. Uterine, liver, spine and brain tissue were also harvested for 
histology and RNA processing. Digesta and fecal samples were collected from the cecum, colon 
and small intestine.  
Burrowing Assay  
To properly determine the pain effect of endometriosis in mice we needed to identify an 
experimental assay that separates the effect of endometriosis from the possibility of the surgery 
itself having an effect. A subset of the mice was used for the burrowing assay. This included one 
mouse that did not receive any treatment or surgery, two ovariectomized mice that received a 
sham surgery and two ovariectomized mice that received the transplantation surgery with 
confirmed lesions at the time of collection (Table 2). We followed a previously established 
protocol for burrowing120,118,119 with a few modifications. The materials required for the 
burrowing assay were: a large mouse cage, burrowing apparatus (PVC pipe with one closed end, 
two screws lifting the open end about an inch off the ground), weighing scale, cup, and substrate 
(food pellets). Mice were allowed to become acclimated to the burrowing system for 3 days prior 
to the beginning of data collection, with contents of the tube refilled every 24 hours. After the 
three day acclimation period had passed the test period was started, the burrowing tube was filled 
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with 200 g of the substrate (food pellets) at 0 hours and then placed into the cage. We then 
weighed the amount of substrate still in the tube every 20 minutes for the first 3 hours. 
Thereafter, the contents of the tube were weighed again at 5-, 7- and 24-hour time points. This 
was repeated every 48 hours for the entire length of the experiment. For the purpose of statistical 
analyses, we grouped the results from control and sham animals at all of the time-points. 
Histochemistry and Immunohistochemistry 
All lesions were processed and stained with Hematoxylin and Eosin to evaluate their 
morphology. Lesions were immunostained for Claudin-4, an epithelial cell marker; Ki67, a 
proliferation marker; and platelet endothelial cell adhesion molecule (PECAM), an endothelial 
marker, using the protocol described in Appendix B. Mouse brain and spinal cord tissue were 
stained for ionized calcium-binding adapter molecule-1 (Iba-1), a marker for microglia in the 
brain and spinal cord. 
Quantification 
Slides were scanned in the Hamamatsu NanoZoomer-XR, a whole slide imaging tool. 
Quantification of the Ki67 and PECAM positive cells was done using NanoZoomer digital 
pathology software to select five, 40x magnification, fields on each histological section for each 
lesion and then drawing lines through each section to create a grid. The positive cells in each 
square of the grid were counted by hand and recorded. The numbers of positive cells in five 
fields per tissue section for each lesion were averaged. Iba-1 quantification was done by locating 
the hippocampal region of the brain and capturing 40x images in the Nanozoomer digital 
pathology software. Iba-1 stained area was quantified using Trainable Weka Segmentation to 
separate the image into 2 classes: Class 1: blue or light blue area, “unstained tissue” and Class 2: 
brown area, “positively stained area”. Once the program was trained to recognize the two areas, a 
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probability map was made and a threshold was set to match with the original NanoZoomer 
image. A measurement of class 2 “brown” area was taken as well as a measurement of class 1 
area to allow quantitation of the percentage of the positively stained area (ie positively stained 
cells) (Appendix C). We examined the hippocampus because of its importance for learning, 
memory and because it is an important location for examining persistent pain.121–123   
Statistical Analysis 
All statistical analysis was done using Graph Pad Prism 7.0. Results were tested for 
Gaussian distribution using the D’Agostino-Pearson omnibus normality test. If data were 
normally-distributed, parametric analysis was done with unpaired two-tailed t-test or ordinary 
one-way ANOVA. If data were not normally-distributed, a non-parametric Mann-Whitney or 
Kruskal-Wallis test was performed. All results are shown as mean ± SEM. A p-value <0.05 was 
considered significant.  
 
RESULTS 
Endometriosis Pilot Study 
In our initial endometriosis trial, we utilized 20 mice supplemented with 100 ng of E 
every four days (Table 1), which resulted in only 11 mice with endometriosis and a total of 16 
lesions. The first collection at day 4 resulted in 100% incidence and every mouse had at least one 
lesion located on the incision site or the fat pad. The second collection at day 8 post-
transplantation surgery showed a 50% incidence, as only three of the six mice that we harvested 
had endometriotic lesions. Five lesions were collected from these three mice and were located on 
the fat pad, surgery site and outside of the uterus. Eight days later at the last collection time-point 
(16 days post-transplantation) we harvested ten mice and found that only 4 four had 
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endometriotic lesions. Each mouse had one lesion and they were all located on the surgery site 
(Figures 4 and 5).  
Lesions were immunostained using the protocol described in Appendix B. We first 
examined lesions using hematoxylin staining and claudin-4 expression in order to confirm the 
presence of endometrial glands in each lesion.  We observed the presence of glands in all lesions 
at every time point confirming that these were endometriotic lesions (Figure 6). 
We found that lesions at every time point had a considerable number of proliferating cells 
(Figure 6). We quantified the numbers of proliferating cells by day of collection and saw that 
there was not a significant difference in the rate of proliferation over time as the disease 
progressed (Figure 7). Angiogenesis is a key factor in establishment and development of 
endometriotic lesions and we carried out immunostaining for PECAM, an endothelial cell 
marker, so that we could visualize blood vessels within the lesions. We found that the lesions had 
already established a robust blood supply by day 4 post-transplantation surgery and maintained 
these blood vessels as the disease progressed (Figure 6). Quantification of the numbers of blood 
vessels in the lesions showed that there was no change in the number of vessels over time as 
lesion development continued (Figure 7).   
Endometriosis Study #2 
In this second trial, where the mice received higher amounts of estradiol, we saw that 11 
of the 18 recipient mice had confirmed lesions (Table 2). Mice collected at the day 4 and 16 
time-points each had only three out of six mice with endometriosis, while 5 of 6 mice collected 
at day 8 had confirmed endometriotic lesions. A total of  three lesions were collected at day 4, 
six lesions collected at day 8 and three lesions collected at day 16 (Figure 8). We analyzed 
lesions for the presence of glands, proliferation, and angiogenesis. Due to the small number of 
20 
 
lesions collected, we were unable to compare levels of proliferation and angiogenesis between 
groups, but we did observe that there was active proliferation in the lesions throughout the time 
course of the experiment. These lesions also had an established blood supply and glands present 
throughout the entire time course of the experiment. (Figure 9).   
We observed that mice with endometriosis were burrowing significantly less and leaving 
more food in the burrowing tubes than the sham surgery or control mice. The similarity of 
burrowing behavior between control and sham mice confirms that the potential residual pain 
from the surgery itself was probably not the cause of decreased burrowing activity. We saw that 
the difference in burrowing behavior was present three days after surgery and continued up until 
the last day of data collection at 14 days post transplantation (Figure 10). Endometriosis is an 
inflammatory disease, so we wanted to examine the brain and spinal cord for signs of 
inflammation outside of the peritoneal cavity. We determined that the mice with endometriosis 
had an increased expression of Iba-1 in the hippocampal region of the brain (Figure 12). We saw 
an increase in the number of positively stained, Iba-1 expressing cells and also observed a 
morphological change with an increase in hypertrophic microglia from the mice with 
endometriosis (Figure 11). We saw similar increased Iba-1 staining  in the spinal column of  













Table 1. Treatment groups for mouse model pilot study. Ovariectomized mice were 
treated with 100 ng E every 4 days starting four days before transplantation. We collected 
four mice at day 4, six mice at day 8 and ten mice at day 16 post-transplantation.   
 
 
Table 2. Treatment groups for endometriosis study #2. Two mice were collected for 
each treatment other than the endometrosis mice with 6 mice collected per time-point 
(days 4, 8 and 16). Mice used for the burrowing assay are noted with asterisks (only 2 







Treatment Day 4 Day 8 Day 16  Total 
ENDOMETRIOSIS  
Ovex mice w/100 ng/4 days E  
w/ Tissue transplantation 
n=4 n=6 n=10 n=20 
Treatment Day 4 Day 8 Day 16  Total 
CONTROL 
 Intact w/o E 
 w/o surgery  
2 2 2* 6 
ESTRADIOL NEGATIVE CONTROL  
Ovex mice w/o E 
 w/o surgery 
2 2 2 6 
ESTRADIOL POSITIVE CONTROL  
Ovex mice w/E 
 w/o surgery 
2 2 2 6 
SHAM SURGERY CONTROL 
Ovex mice w/ 1 µg E  
w/ sham surgery 
2 2 2* 6 
ENDOMETRIOSIS  
Ovex mice w/ 1 µg E  
w/ surgery and tissue transplantation 




























Figure 4. Endometriosis pilot study: endometriotic lesions in mice. Endometriotic 
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Figure 5. Endometriosis pilot study: incidence of endometriosis and number of lesions 
collected. (A) 100% of mice collected at day 4 had endometriosis, 50% of mice collected at day 
8 had endometriosis, and 40% of mice collected at day 16 had endometriosis. (B) At day 4, we 
collected a total of six lesions from 4 mice; at day 8, we collected a total of five lesions from 6 










































Figure 6. Endometriosis pilot study: histology and morphology of lesions. Hematoxylin 
and Eosin staining of endometriotic lesions at (A) day 4 (B) day 8 and (C) day 16. (Stromal 
cells are indicated by blue arrows and glands are indicated by orange arrows.) Presence of 
glands was confirmed with Claudin-4 staining at (D) day 4 (E) day 8 and (F) day 16; Ki67 
expression in the lesions is shown at (G) day 4 (H) day 8 and (I) day 16; PECAM expression 
in endometriotic lesions is shown at (J) day 4 (K) day (8) and (L) day 16. Images are at 40X 
and inset images at 2.5X. 
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Figure 7. Endometriosis pilot study: quantification of Ki67 and PECAM 
immunostaining. (A) Average number of Ki67 positive, proliferating cells. 
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Figure 8. Endometriosis study #2: incidence of endometriosis and number of lesions 
collected. (A) 50% of mice at day 4 had endometriosis, 83% of mice collected at day 8 had 
endometriosis and 50% of mice collected at day 16 had endometriosis. (B) At day 4, we 
collected a total of three lesions from 6 mice; at day 8, we collected a total of six lesions from 6 
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Figure 9. Endometriosis study #2: histology and morphology of lesions. Hematoxylin and 
Eosin staining of endometriotic lesions at (A) day 4 (B) day 8 (C) day 16. (Stromal cells are 
indicated by blue arrows, glands are indicated by orange arrows). Presence of glands was 
confirmed with Claudin-4 staining at (D) day 4 (E) day 8 and  (F) day 16; Ki67 expression in 
the lesions is shown at (G) day 4 (H) day 8  and (I) day 16; PECAM expression in 
endometriotic lesions is shown at (J) day 4 (K) day (8) and (L) day 16. Images are at 40X and 
inset images at 2.5X. 
 
 
































    0hr     24hr 0hr                          24hr 0hr   24hr 
A 
Figure 10. Endometriosis Study #2: Burrowing assay. (A) Individual burrowing activity 
patterns of mice at days 6 to 10 after surgery. Sham mice and control mouse showed 
similar patterns of burrowing. (B) Control and sham surgery mice were grouped into one 
group called the control mice without endometriosis and mice with endometriosis were 
grouped for analysis from day 3 post tissue transplantation, until 14 days post 
transplantation. Increased amounts of food left in the burrowing tubes indicated decreased 
burrowing behavior by mice with endometriosis compared to the mice without 


































Ramified (Quiescent) Amoeboid Hypertrophic (Activated) 
Figure 11. Endometriosis Study #2: Activation of microglia in the brain. 
 (A) Morphological changes in microglia when activated. Iba-1 staining for microglia in the 
hippocampal region of the brain at (B) day 4 control (C) day 4 with endometriosis; (D) day 8 





































































Figure 12. Endometriosis Study #2: Quantification of Iba-1 expression. A 40X image of 
the brain was quantified using FIJI software. Control mice from all time points were 





























Figure 13. Endometriosis Study #2: Microglia in the dorsal root of the spinal cord. 
Spinal columns were immunostained with Iba-1. (A) Day 4 control mouse without 
endometriosis and (B) day 4 mouse with endometriosis, showing increased number and 






Both of our experimental trials resulted in endometriotic lesions that mimic lesions found 
in humans. Our first pilot study did not show the expected incidence of endometriosis. For that 
reason, we chose to increase the estradiol supplementation to 1 µg every four days. The increase 
in supplemental estradiol in our second trial did not solve this problem because we still saw a 
lower incidence of endometriosis than expected.  
The fact that we saw decreased incidence of lesions in both of these trials with two doses 
of estradiol suggests that estradiol is not the only factor for induction of endometriosis. There 
must be an immune response occurring that was clearing the lesions. The hormone level was 
sufficient for implantation of lesions but peritoneal macrophages could have responded to the 
attachment and signaled for phagocytosis, thus they were not able to survive to the later days of 
collection. The population of phagocytic macrophages in women with endometriosis have been 
shown with decreases in phagocytic capabilities.7,90 To increase the incidence in our model using 
immune-incompetent mice, a transplantation model with an inbred mouse strain could be useful 
to decrease this phagocytic macrophage response.  
There is little in the current literature regarding assessment of pain due to endometriosis 
in animal models of this disease. We were able to determine that mice with endometriosis were 
in pain/discomfort because of their decreased burrowing activity. Identifying this sensitive pain 
response spurred us to investigate whether there may be signals sent to the brain activating the 
immune cells there. In fact, we did see an increase in the population of activated microglia in the 
brain and spinal tissue of mice with endometriosis compared to controls.  Microglia are the 
resident immune cells in the brain and spinal cord. During their resting or quiescent state, they 
have long outstretched processes that are constantly scanning the brain to maintain homeostasis. 
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The cells can become activated or hypertrophic when they encounter a perturbation and will then 
become amoeboid to gain motility for the ability throughout the brain to remedy the situation, 
normally phagocytosing a dead or damaged neuron, that caused the initial activation121–124 
(Figure 8). Chronically activated microglia can cause damage to neurons by phagocytizing 
healthy cells. The chronically activated cells can also release reactive oxygen species and other 
cytotoxins.121–124  The damage caused by chronically activated microglia can contribute to 
neurodegenerative diseases later on in life, such as Parkinson’s disease, Alzheimer’s disease, and 
dimentia.121–125 This is a concern for women with chronic pain and inflammation from 
endometriosis. Confirmation of the presence of activated microglia in the brain of mice with 
endometriotic lesions from each time point collected indicates that the microglia are activated 
early in the development of the disease and that this activation remains until at least 16 days 
post-transplantation in this model. Women with endometriosis could also have activated 
microglia in their brains as evidenced by the increased visceral pain caused by endometriosis, 
and these cells may remain chronically activated throughout the duration of the disease. This can 
be a serious problem considering that many women have endometriosis for years without being 
diagnosed, and additional years could go by before successful treatment of the disease occurs.126–
128 Moreover, some women never undergo treatment or surgery to remove the lesions. There is 
also a high probability for reoccurrence following surgery, adding additional years with 
chronically activated microglia potentially predisposing these women to neurodegenerative 
diseases later in life.  
The results of these two trials show that the transplantation mouse model is sufficient to 
produce endometriotic lesions in mice that are very similar to those found in women. Ideally we 
would prefer to have an animal model that has a higher incidence so that more analysis can be 
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done with a smaller number of animals used. We also validated the burrowing assay as a tool that 
can be used to assess pain in mice with endometriosis. Moreover, we showed that microglia in 
the brain and spinal column show increased activation in the mice that have endometriotic 






















CHAPTER 3: GENETIC IMPACT ON ENDOMETRIOSIS MOUSE MODEL 
INTRODUCTION 
 There are currently several different models for inducing endometriosis in laboratory 
rodent species. Many researchers have been successful using either auto-transplantation or 
transplantation of syngeneic tissue into the peritoneal cavity in rats and mice. Studies in the 
literature have reported the effective establishment of endometriosis in mouse models utilizing  
tissue transplantation into C57BL/6 mice supplemented with synthetic estradiol instead of 17β-
estradiol.6,25,129,130 In our previous studies in CD-1 mice (see Ch. 2), supplementation with 17β-
estradiol at doses of 100 ng and 1 µg resulted in decreased incidence of endometriotic lesions 
that was lower than expected. Estradiol valerate is a synthetic estrogen, or estradiol ester, that is 
metabolized at a slower rate than 17β-estradiol. This reduced rate of metabolism is because of 
the need to cleave estradiol valerate into 17β-estradiol and valeric acid before it can act on the 
body as a biologically active estrogen (Figure 11).  Treatment with estradiol valerate has been 
shown to result in more stable serum estradiol levels with fewer peaks and troughs in several 
animal species.131–133 This more stable profile in estradiol levels could be important for 
promoting implantation of transplanted tissue and progression of endometriotic lesions. 
In this experiment we chose to compare two strains of mice, CD-1 and C57BL/6. CD-1 
mice are an outbred line, while C57BL/6 mice are an inbred line. C57BL/6 mice are guaranteed 
to come from a line of at least 20 generations of brother and sister matings that result in all mice 
being as genetically similar as possible.134  CD-1 mice are maintained for genetic diversity and 
are also monitored to make sure they are still genetically linked.135 This difference in genetic 
background is important when performing animal model experiments, as it is a source of 
variation. Therefore, we wanted to determine if there is a genetic impact on the incidence of 
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endometriosis and also, if a change in the type of estradiol supplementation may support an 
increased induction of disease. 
METHODS 
Animal experiments were approved by the University of Illinois Institutional Animal 
Care and Use Committee and followed the guidelines of the National Institute of Health 
standards for the use and care of animals. Female CD-1 and C57BL/6 mice were purchased from 
Charles River. Mice were kept in a standard light and temperature-controlled animal facility (12 
h day light: 12 h dark) and provided with Teklad diet 7013 and water ad libitum. 
Female mice (6-8 weeks old) were anesthetized with Ketamine/Xylazine (87 mg/kg; 15 
mg/kg i.p.). A 1 cm dorsal midline incision was made through the skin, then two 0.5 cm incisions 
were made through the muscle lateral to the midline. The ovaries were located and removed by 
clamping the ovarian stalk and cutting the ovarian tissue out, the oviduct was ligated to prevent 
excess bleeding. Following ligation, sterile absorbable sutures were used to close the muscle 
layers. Skin incisions were closed with wound clips and mice were allowed to recover on a 
warming pad. Buprenorphine (0.05 mg/kg, subcutaneously) was given as an analgesic to 
minimize pain and discomfort one hour before administering anesthesia and 6-10 hours after the 
initial dose. Animals were monitored every day, and wound clips were removed 10 days post-
surgery. 
Syngeneic female mice were used as a source of donor tissue. The donor mice were 
primed with 5 IU of pregnant mare serum gonadotropin (PMSG; i.p.) 48 hours prior to 
euthanasia and harvesting of the uterus to stimulate growth of the uterus. Transplantation of 
tissue was performed as follows. Uterine tissues were collected from donor mice, chopped into 
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smaller pieces (<0.5 mm), washed in sterile phosphate buffered saline (PBS), and suspended in 
1.0 ml of PBS at room temperature.  
Recipient mice were anesthetized 14 days after ovariectomy using the same cocktail as 
for the previous surgery (Ketamine/Xylazine 87 mg/kg; 15 mg/kg; i.p.). A 0.5 cm dorsolateral 
incision was made, and 0.5 ml of uterine fragment suspension was gently injected into the 
peritoneal cavity of the recipient mouse, using the uterine tissue from one donor mice for two 
recipient mice. After the introduction of the tissue into the peritoneal cavity, closure of the 
muscle layer was accomplished with sterile absorbable suture and skin incisions with wound 
clips.  Recipient mice were given buprenorphine (0.05 mg/kg, subcutaneously) 1 hour prior to 
administering anesthesia and 6-10 hours after initial dose to reduce discomfort and pain from 
surgery. Recipient mice were injected subcutaneously with the first dose of estradiol 
valerate (2.5 µg/mouse) diluted in corn oil seven days before the transplantation surgery.  
Injections were continued every seven days until euthanasia to help maintain disease 
progression.  
Recipients were euthanized at 21 days after transplantation and transcardially perfused 
with sterile PBS. The number, location, and size of ectopic lesions were recorded, and the 
collected lesions were stored in 10% neutral buffered formalin. Uterine, liver, spine and brain 
tissues were also harvested for histology and RNA processing. Digesta and fecal samples were 
collected from the cecum, colon, and small intestine.  
  We utilized a total of eight CD-1 and seven C57BL/6 ovariectomized recipient mice that 
received 2.5 µg of estradiol valerate (in corn oil) subcutaneously once every seven days until 





Histological sections were prepared as described in Appendix B. Slides with tissue were 
immune-stained for claudin-4 and scanned in the Hamamatsu NanoZoomer-XR, a whole slide 
imaging tool. Using NanoZoomer digital pathology software, each gland was identified and 
magnified. The freehand region tool was used to trace the positively stained epithelial cells 
(Figure 12). This was repeated for all the visualized glands, resulting in number of glands and 
area of glands in mm2 or µm2. All values were converted to mm2 and all the gland area 
measurements from one endometriotic lesion were summed to determine the total gland area per 
lesion.   
Statistical Analysis 
All statistical analyses were performed using Graph Pad Prism 7.0. Results were tested 
for Gaussian distribution using the D’Agostino-Pearson omnibus normality test. If data were 
normally distributed, then parametric analysis was done with unpaired two-tailed t-test or 
ordinary one-way ANOVA. If data were not normally distributed, then a non-parametric Mann-
Whitney or Kruskal-Wallis test was performed. All results are shown as mean ± SEM. A p-value 
<0.05 was considered significant.  
RESULTS 
 All seven C57BL/6 mice harvested had lesions, with 18 lesions collected in total and an 
average of 2.6 lesions per mouse (Figures 16 and 17). Lesions from these mice were located in a 
variety of places in the peritoneal cavity including the peritoneal wall, fat pad, and the mesentery 
of the uterus and intestines. The lesions collected from the C57BL/6 mice were uniform in 
appearance and were clear, fluid filled and cyst-like (Figure 18). The lesions collected from the 
C57BL/6 mice were also much larger than lesions collected from the CD-1 mice from this study 
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(Figure 17). Only three of the eight CD-1 mice collected had endometriotic lesions, with each 
mouse only having one lesion (Figures 16 and 17). The lesions from the CD-1 mice were found 
on the peritoneal wall or the fat pad. There was more variability in the appearance of the lesions 
found in these mice. Lesions were brown, pink, or yellow in color, but we did have one lesion 
that looked similar to the more cyst-like lesions found in the C57BL/6 mice (Figure 18).  
There were also some differences in the appearance of the uteri between these two strains 
of mice. The uteri from the C57BL/6 mice were extremely large and appeared clear and 
engorged, while the uteri from the CD-1 mice looked healthy, developed and pink in color 
(Figure 19). We first examined lesions using hematoxylin staining and claudin-4 expression in 
order to confirm the presence of endometrial glands in each lesion (Figure 20). Using this marker 
we saw the presence of glands in the lesions collected from both strains of mice. C57BL/6 mice 
had more glands in the endometriotic tissue and the glands were larger in the C57BL/6 mice 















































Collected at day 21 post transplantation CD-1 strain C57BL/6 strain Total 
ENDOMETRIOSIS  
Ovex mice w/2.5 µg Estradiol Valerate 
 w/ Surgery and tissue transplantation 
n=8 n=7 n=15 
A B 














































Figure 15. Measuring area of glands. (A) Picture at 20X magnification showing claudin-4 
staining. (B) The same image with tracing of the area of glands using NanoZoomer digital 







































Figure 16. Incidence of endometriosis and number of lesions. (A) 37.5% of the CD-1 
mice were collected with endometriosis and 100% of the C57BL/6 mice collected had 
endometriosis. (B) Total number of lesions collected from each strain, 3 lesions from CD-























































Figure 17. Number and volume of lesions. (A) Number of lesions per mouse. Each CD-1 
mouse had 1 lesion while C57BL-6 strain had an average of 2.6 lesions per mouse. (B) 












































Figure 18. Endometriotic lesions in mice. (A-C) Lesions in CD-1 mice. (A) Lesion in 
peritoneal wall, (B) cyst-like lesion on the peritoneal wall, and (C) brown lesion in the 
fat pad. (D-F) Lesions in C57BL/6 mice. (D) Two large cyst-like lesions in the fat pad 
and mesentery of the uterus, (E) cyst-like lesions on peritoneal wall connected to 


















































Figure 19. Comparison of uterine size. (A) CD-1 uterus and (B) C57BL/6 uterus. Blue 

























































Figure 20. Hematoxylin and eosin for morphology of lesions. Hematoxylin and eosin 
staining of endometriotic lesions. Lesions in CD-1 mice (A) lesion in peritoneal wall, (B) 
cyst-like lesion on the peritoneal wall, and (C)  lesion in the fat pad. Lesions in C57BL/6 
mice. (D) Two large cyst-like lesions in the fat pad and mesentery of the uterus, (E) large 
cluster of cyst-like lesions on the peritoneal wall, and (F) cyst-like lesions on peritoneal wall 
connected to uterine mesentery. (Stromal cells pointed by blue arrows, glands pointed by 











































































































Figure 21. Number and area of glands. (A) Number of glands in CD-1 mice is 
lower than in C57BL/6 mice. (B) Area of the glands in CD-1 mice is less than the 




A tissue transplantation model for endometriosis is ideal when syngeneic animals are 
used as donors of the tissue for transplantation into recipient mice. This will help minimize an 
immune response which would lead to tissue rejection and result in failure to induce 
endometriotic lesions. To overcome this problem, many research groups use auto-transplantation 
models where the donor uterine tissue to be used for induction of endometriosis is from the same 
mouse that is the recipient mouse.9,26,27,37,136 These models require additional, lengthier surgeries 
for the recipient animal and a reduced amount of donor tissue is available for transplantation.  
We first used CD-1 mice as donors and recipients. However, this is technically an allogeneic 
model because these mice are an outbred line as mentioned above, there is the potential for a 
stronger immune response and tissue rejection due to an increased allogeneicity. Since the 
C57BL/6 mice are technically genetically identical, there is less genetic variability among them, 
and in this model the recipient and donor mice are more syngeneic than the CD-1 mice. This 
would more closely resemble the situation in women who develop this disease. Women with 
endometriosis slough their own endometrium, which reversely flows into their peritoneal cavity, 
where this tissue can attach and develop into endometriotic lesions. In a sense, endometriosis in 
women is an auto-transplantation of endometrial tissue that does not elicit this initial rejection 
immune response. Women with endometriosis have a decreased immune response, aiding in 
implantation instead of rejection of tissue.7,90,129 We believe that we are seeing a similar more 
permissive immune response in the C57BL/6 mice, making this a better strain to utilize as a 
model to study endometriosis.  
Endometriosis has a very significant genetic component and is a multi-factorial disease. 
For example, if a woman has a relative in her immediate family with endometriosis, she is five to 
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seven times more likely to also have endometriosis when compared to women with no immediate 
relative affected.7,137–141 The incidence of endometriosis has been monitored in a colony of 
rhesus macaques, showing a strong familial correlation as well as an overall colony rate of 
31.4% with endometriosis.142 Many of these studies showing a familial inheritance of 
endometriosis support the hypothesis that there is a genetic component to the disease. Due to the 
increased number of endometriotic lesions found in C57BL/6 mice, it is possible that this strain 
of mice has a similar genetic mutation or polymorphism that women in affected families or 
rhesus macaque colonies with endometriosis also have.  
Endometriotic tissue originates from the uterus so it responds to hormones similarly to 
the uterus and is estrogen-dependent.116,143 Due to the size difference of the uteri from both of 
these mouse strains treated with the same dose of estradiol valerate, it is apparent that the uterine 
tissue responds differently in the two strains. C57BL/6 mice uteri were larger than the CD-1 uteri 
suggesting that the endometriotic lesion tissue in these mice also showed a greater response 
similar to the uteri, resulting in increased size and incidence of endometriotic lesions found in 
C57BL/6 mice. Thus, in addition to a decreased initial immune response that we believe is 
occurring in C57BL/6 mice, these mice also appear to be more responsive to estrogen, providing 
a more robust model than the CD-1 mice.  
In a healthy uterus, the endometrial glands are important for secreting growth factors and 
cytokines to prepare for a potential pregnancy with each menstrual cycle.116,144 In an 
endometriotic lesion, the glands are also secreting similar growth factors, angiogenic factors, and 
anti-apoptotic signals that promote development and growth of endometriosis.90,116 The increased 
number and size of glands in the lesions collected from C57BL/6 mice are indicative of 
increased secretory function, perhaps in response to estrogen, suggesting that these lesions could 
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be developing and growing larger due to the secretion of growth factors and anti-apoptotic 
factors acting in an autocrine manner. The smaller number and size of endometrial glands in the 
CD-1 derived lesions could be due to a greater immune response leading to clearing of 
endometrial fragments before they can attach or to a suboptimal response to estrogen leading to 





















CHAPTER 4: THE EFFECT OF DI (2-ETHYHEXYL) PHTHALATE (DEHP) ON 





 Di (2-ethylhexyl) phthalate, DEHP, is a chemical phthalate that is used as a plasticizer in 
many hard plastics to create a more flexible and malleable product. Phthalates are also found in 
many common personal care products such as soaps, shampoos, and lotions. These chemicals  
leach easily from products and are ingested, inhaled or absorbed through dermal contact.48,56,78 
Large studies confirm the presence of DEHP and other phthalate metabolites in the urine of 
people from many different career paths and lifestyles.62 DEHP is a known endocrine-disrupting 
chemical with reported negative effects on the hypothalamus and the reproductive tracts of both 
male and female laboratory animals.69–78 DEHP is rapidly metabolized into mono- (2-ethylhexyl) 
phthalate, MEHP, upon entering the body. MEHP has a half-life of five hours and is also quickly 
oxidized, resulting in metabolites that have longer half-lives of 24 hours and are found in the 
urine for a greater period than MEHP following exposure.55 Studies have shown that DEHP and 
its metabolites are excreted in the urine in a relatively short amount of time but, with constant 
exposure from the environment, these metabolites can accumulate and cause damage. The 
mechanisms by which DEHP and its metabolites act on the female reproductive system is not 
clear, although there have been some studies showing that MEHP may modulate peroxisome 
proliferator-activated receptors (PPARs).77,82 PPARγ, an isoform of PPAR, has been discovered 
to dysregulate endometrial functions in uterine tissue from rats treated with estrogens and 
phytoestrogens.145 Since endometriosis is the presence of endometrial tissue outside of the 
uterus, the mechanisms by which DEHP acts on the endometrium in the uterus could be similar 
to its actions on endometriotic lesions.  The goal of this study was to examine the effects of 
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DEHP on the development of endometriosis in a mouse model, particularly its effects on 
proliferation, angiogenesis, and inflammation within the endometriotic lesions. With our 
previous results showing that burrowing activity is significantly decreased in mice with 
endometriosis, we wanted to further investigate the effects of endometriosis on visceral 
pain/discomfort and determine whether DEHP exposure alters microglia activation in the brain 
and spinal cord.  
METHODS 
 Animal experiments were approved by the University of Illinois Institutional Animal 
Care and Use Committee and followed the guidelines of the National Institute of Health 
standards for the use and care of animals. Female C57BL/6 mice were purchased from Charles 
River Laboratories. Mice were kept in a standard light controlled animal facility (12 h daylight: 
12 h dark) and provided with Teklad diet 2920x and water ad libitum. 
Recipient mice were dosed daily, starting seven days prior to transplantation, with 
subcutaneous injections of vehicle control (corn oil), 30 mg/kg or 60 mg/kg DEHP in corn oil, 
(Table 4). Five days after the start of dosing the recipient mice, syngeneic female donor mice 
were primed with 5 IU of pregnant mare serum gonadotropin (PMSG; i.p.)  48 hours prior to 
euthanasia and harvesting of the uterus, in order to stimulate the growth of the uterus.  
Transplantation of tissue was performed as follows. Uterine tissues were collected from donor 
mice and chopped into smaller pieces (<0.5 mm), washed in sterile phosphate buffered saline, 
and suspended in 1.0 ml of PBS at room temperature. Recipient mice were anesthetized using 
Ketamine/Xylazine (87 mg/kg; 15 mg/kg; i.p.).  A 0.5 cm dorsolateral incision was made and 0.5 
ml of uterine fragment suspension was gently injected into the peritoneal cavity of the recipient 
mouse, using the uterine tissue from one donor mice for two recipient mice. After the 
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introduction of the tissue into the peritoneal cavity, closure of the muscle layer was 
accomplished with sterile absorbable suture and skin incisions with wound clips.  Recipient mice 
were given buprenorphine (0.05 mg/kg) 1 hour prior to administering anesthesia and 6-10 hours 
after the initial dose to reduce discomfort and pain from surgery.  Sham surgery was done to 
control for the effects of daily injections and surgery as these are potential causes of increased 
pain or inflammation; two groups of mice were treated daily with the vehicle control or 60 mg/kg 
DEHP and given 0.5 ml of PBS only and did not receive any transplanted uterine tissue 
fragments.   
Recipient mice were euthanized in estrus at ~4, ~8, ~16, and ~32 days after tissue 
transplantation and weighed. Vaginal smears were performed daily with sterile PBS to determine 
when mice were in estrus and ready for tissue harvest. The peritoneal cavity of each mouse was 
gently rinsed with 2 ml of PBS and then collected. Mice were transcardially perfused with sterile 
PBS, the number, location, and sizes of ectopic lesions were recorded, and lesions collected into 
10% neutral buffered formalin. Uterine, liver, spine, and brain tissues were also harvested.  
Digesta and fecal samples were collected from the cecum, colon, and small intestine.  
Histology and immunohistochemistry 
All lesions were processed and stained with hematoxylin and eosin to evaluate their 
morphology. Lesions were immunostained for proliferation marker Ki67, the endothelial cell 
marker platelet endothelial cell adhesion molecule (PECAM), and the macrophage marker 
cluster of differentiation 68 (CD68). Mouse brain tissue was immunostained for ionized calcium-
binding adapter molecule-1 (Iba-1), a marker for microglia in the brain and spinal cord. Lesions 
were immunostained using the protocol described in Appendix B. 
Quantification using FIJI 
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Slides were scanned in the Hamamatsu NanoZoomer-XR, a whole slide imaging tool. 
Using NanoZoomer digital pathology software, sections of tissue were magnified to capture the 
entire lesion. A scale bar was placed in an area not covered by tissue. The image was exported 
and uploaded into Fiji software. The scale of the image was set using the scale bar for each 
picture. Any excess fat or muscle that was connected to the endometriotic lesions was excluded 
from the picture as well as the scale bar. Trainable Weka Segmentation was used with the 
adjusted image to separate the image into 3 classes: Class 1 white or black “empty space”, Class 
2 blue or light blue area “unstained tissue” and Class 3 brown area “positively stained area”. 
Once the program was trained to recognize these three areas, a probability map was made and a 
threshold was set to match with the original Nanozoomer image. A measurement of Class 3 
“brown” area was taken as well as a measurement of the class 2 area to allow for quantitation of 
the percentage of positively stained area. Iba-1 quantification was done by locating the 
hippocampal region of the brain and capturing 10x images in the Nanozoomer digital pathology 
software. Iba-1 stained area was quantified in the same manner, but quantification of the positive 
Iba-1 stained area was done using Trainable Weka Segmentation to separate the image into 2 
classes: Class 1: blue or light blue area, “unstained tissue” and Class 2: brown area, “positively 
stained area”. Once the program was trained to recognize the two areas, a probability map was 
made and a threshold was set to match with the original NanoZoomer image. A measurement of 
class 2 “brown” area was taken as well as a measurement of class 1 area to allow quantitation of 
the percentage of the positively stained area (Appendix C).  
Burrowing Assay  
We followed an established protocol, previously described, for burrowing120,118,119 with a 
few modifications. The materials required for the burrowing assay were a large mouse cage, 
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burrowing apparatus (PVC pipe with one closed end, two screws lifting the open end about an 
inch off the ground), weighing scale, cup, and substrate (food pellets). The mice were allowed to 
become acclimated to the burrowing system for 3 days prior to the beginning of data collection, 
with refilling of substrate into the tube every 24 hours. After the three days, the burrowing tube 
was filled with 125 g of the substrate (food pellets) at 0 hours and placed into the cage. We then 
weighed the amount of pellets remaining in the tube every 20 minutes for the first 3 hours. 
Thereafter, the contents of the tubes were weighed at 5, 7 and 24 hour time points. The tube was 
refilled and measurements repeated every 48 hours for the entire length of the experiment. 
Animals that were used for the burrowing assay are noted with asterisks in Table 1. 
Statistical Analysis 
All statistical analysis was done using Graph Pad Prism 7.0. Results were tested for 
Gaussian distribution using the D’Agostino-Pearson omnibus normality test. If data were 
normally distributed, then parametric analysis was done with unpaired two-tailed t-test or 
ordinary one-way ANOVA. If data were not normally distributed, then a non-parametric Mann-
Whitney or Kruskal-Wallis test was performed. All results are shown as mean ± SEM. A p value 
<0.05 was considered significant.  
RESULTS 
 
Endometriotic lesions were found in the mice at all four time-points in a variety of 
locations in the peritoneal cavity (Figure 22). In the mice given endometriosis and treated with 
vehicle control, there were seven lesions collected from four of the six mice culled at the day 4 
post-transplantation time-point. At day 8 post-transplantation, there were six lesions collected 
from four of six mice culled. All of the mice collected at day 16 had endometriosis with seven 
lesions collected. At the last collection point on day 32, we only collected two lesions from two 
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of the six mice culled. In the 30 mg/kg DEHP group, at day 4, we collected 12 lesions from five 
of six mice culled. At the day 8 time-point, we only found two lesions from one of the six mice. 
At day 16, four lesions were collected from two of the five mice culled. We did see an increase 
in the number of lesions at day 32, with 10 lesions collected from five of the five mice culled. In 
the 60 mg/kg DEHP treatment group, we collected 10 lesions from six of six mice culled at day 
4. At day 8, six lesions were collected from four of six mice culled. At day 16, there were seven 
lesions collected from five of seven mice culled. At the last time-point on day 32, seven lesions 
were collected from five of the seven mice culled (Figure 23). Overall, there was no effect of 
DEHP treatment on the incidence of lesions. However, at day 32, there was a higher incidence in 
the 30 mg/kg DEHP group, with eight more lesions collected than in the vehicle control group. 
Mice treated with the 30 mg/kg DEHP dose had more endometriotic lesions, and the lesions were 
significantly larger than the lesions collected from the mice with endometriosis and treated with 
the vehicle control or the 60 mg/kg DEHP dose (Figure 24).  
We examined lesions using hematoxylin and eosin staining to confirm the presence of 
endometrial stromal cells and glands within each lesion. We were able to identify glands in the 
lesions at every time-point for every treatment group (Figure 25).We found that lesions in every 
treatment group and at each time-point had a considerable number of proliferating cells (Figure 
26). Moreover, we determined that there was a significant increase in Ki67 expression in all 
lesions from mice treated with 30 or 60 mg/kg DEHP compared to the endometriotic lesions 
from mice treated with vehicle control (Figure 27). Angiogenesis is a key factor in establishment 
and development of endometriotic lesions, and we carried out immunostaining for PECAM, an 
endothelial cell marker, in order to visualize blood vessels within the lesions (Figure 28). All of 
the lesions had a very robust blood supply, with positive PECAM staining averaging at 5.7% of 
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the lesion area. We found that the establishment of the blood supply or the number of endothelial 
cells was not affected by DEHP treatment or by progression of the disease (Figure 29). 
Immunostaining of lesions for CD68 to visualize macrophages revealed relatively small numbers 
of these cells in all of the lesions (Figure 30).  Quantification showed that there was no 
significant effect of treatment or time-point on macrophage numbers (Figure 31). 
We observed that mice with endometriosis burrowed significantly less and left more food 
in the burrowing tubes than the control or the sham-surgery with either treatment of vehicle or 
DEHP. The similarity in burrowing behavior between control and sham-surgery mice confirmed 
that the possible residual pain from surgery was not the cause of decreased burrowing activity in 
the mice with endometriosis. There also was no significant difference in burrowing activity 
between the control and sham-surgery mice treated with the vehicle and the sham-surgery mice 
treated with DEHP. In the mice with endometriosis we observed that the difference in burrowing 
activity was already present beginning at two days after surgery and persisted until the last day of 
data collection at 28 days post-transplantation. The decreased burrowing activity was 
significantly different at the 20 minute, 1 hour, 2 hour, 3 hour, 5 hour, and 7 hour time-points; 
however, there was no significant difference in amount burrowed at 24 hours after the 
introduction of the full tube (Figure 32). We also saw no difference in the burrowing behavior 
displayed by the mice that were given the SHAM surgery and treated with DEHP compared to 
the control mice and the vehicle control mice (Figure 32).  
The decreased burrowing activity in mice with endometriosis suggested that these mice 
were experiencing significant pain/discomfort. We therefore wanted to analyze the brain and 
spinal cord for signs of inflammation outside of the peritoneal cavity by quantifying the numbers 
of microglia. We saw an increase in the number of Iba-1 positive glial cells, and also observed 
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morphological changes with an increase in hypertrophic microglia in the mice with 
endometriosis (Figure 33). Quantifying these cells showed that the mice with endometriosis have 
a significant increase in the expression of Iba-1 positive cells in the hippocampal region of the 
brain (Figures 34). We also found that the mice with the sham surgery and treated with 60 mg/kg 
DEHP had more Iba-1 positively stained cells than the control or sham vehicle control treated 
mice (Figures 33 and 34). There was also an increase in expression found in mice with 
endometriosis and treated with DEHP compared to mice with endometriosis and treated with the 
vehicle control (Figure 34). We saw similar increased Iba-1 immunostaining in the spinal column 





















Table 4. Treatment groups for DEHP study. Five to Seven mice were collected for each 
treatment group and time-point (days 4, 8, 16 and 32). Four of the asterisked mice from each 




















Treatment Day 4 Day 8 Day 16  Day 32 Total 
CONTROL 
 w/o daily injections 
 w/o surgery 
n=6  n=6 n=6 n=6* n=24 
SHAM + VEHICLE  
w/daily oil injections  
w/surgery no tissue transplantation  
n=6 n=6 n=5 n=6* n=23 
SHAM + DEHP 
w/daily 60mg/kg DEHP injections 
w/surgery no tissue transplantation 
n=6 n=6 n=5 n=6* n=23 
ENDOMETRIOSIS +VEHICLE  
w/daily oil injections  
w/surgery with tissue transplantation 
n=6 n=6 n=6 n=6* n=24 
ENDOMETRIOSIS + DEHP   
w/daily 30mg/kg DEHP injections 
w/surgery with tissue transplantation 
n=6 n=6 n=5 n=5* n=23 
ENDOMETRIOSIS + DEHP   
w/daily 60mg/kg DEHP injections 
w/surgery with tissue transplantation  









































Figure 22. DEHP study: endometriotic lesions in mice. Endometriotic lesions collected at (A) day 
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Figure 23. Incidence of Endometriosis and number of lesions collected. (A) 
Percentage of mice with confirmed endometriosis at each collection time-point for each 
treatment. (B) Total number of endometriotic lesions harvested from each treatment 





































Figure 24. Volume of lesions, incidence and number of lesions by treatment 
group. (A) Incidence of endometriosis by treatment. (B) Number of lesions 




















































































































Day 4  
Day 8  
Day 16  
Day 32  
Vehicle Control DEHP 30mg/kg DEHP 60mg/kg 
Figure 25. Histology and morphology of lesions in DEHP study. Hematoxylin and eosin 
staining of endometriotic lesions from mice treated with vehicle control (A) day 4 (B) day 8 
(C) day 16 (D) day 32. Lesions from 30mg/kg DEHP dosing group (E) day 4 (F) day 8 (G) 
day 16 (H) day 32. Lesions from mice treated with 60mg/kg DEHP (I) day 4 (J) day 8 (K) 
day 16 (L) day 32. (Stromal cells are indicated by blue arrows and glands are indicated by 
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Day 4  
Day 8  
Day 16  
Day 32  
 Vehicle Control DEHP 30mg/kg DEHP 60mg/kg 
Figure 26. Expression of proliferation marker Ki67 in endometriotic lesions. Ki67 
expression identified proliferating cells in lesions from mice treated with vehicle control 
(A) day 4 (B) day 8 (C) day 16 (D) day 32; lesions from 30mg/kg DEHP dosing group (E) 
day 4 (F) day 8 (G) day 16 (H) day 32; and lesions from mice treated with 60mg/kg DEHP 
(I) day 4 (J) day 8 (K) day 16 (L) day 32. Images are at 40x magnification and inset images 
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Figure 27. Assessment of Ki67 expression in endometrotic lesions. Ki67 expression in 
endometriotic lesions did not significantly differ by (A) collection time but when time-
points were grouped (B) there was a significant increase in expression in the 30mg/kg 













































Figure 28. PECAM expression in endometriotic lesions. PECAM expression showing 
blood vessels in lesions from mice treated with vehicle control (A) day 4 (B) day 8 (C) 
day 16 (D) day 32; lesions from 30mg/kg DEHP dosing group (E) day 4 (F) day 8 (G) day 
16 (H) day 32; and lesions from mice treated with 60mg/kg DEHP (I) day 4 (J) day 8 (K) 
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Figure 29. Quantification of PECAM expression. PECAM expression in endometriotic 
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Day 32  
Vehicle Control DEHP 30mg/kg DEHP 60mg/kg 
Figure 30. CD68 expression in endometriotic lesions. CD68 expression identifying 
macrophages in lesions from mice treated with vehicle control (A) day 4 (B) day 8 (C) 
day 16 (D) day 32; lesions from the 30mg/kg DEHP dosing group (E) day 4 (F) day 8 
(G) day 16 (H) day 32; and lesions from mice treated with 60mg/kg DEHP (I) day 4 (J) 
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Figure 31. CD68 expression in endometriotic lesions. CD68 expression in 



















































C o n tro l

































* * * * * *
* *
*
C o n tro l
E n d o m e trio s is
                     20min  2hr       3hr       5hr      7hr 24hr 
Figure 32. Burrowing assay. (A) Significantly more food was left in the burrowing tubes 
of mice with endometriosis compared with control, demonstrating decreased burrowing 
activity. 20 minutes after introduction of the burrowing tube (***p=0.0008), 2 hours 
(***p=0.0009), 3 hours (***p=0.0002), 5 hours (**p=0.0067), 7 hours (*p=0.0.118).        
(B) There was not a significant difference in the burrowing behavior of the mice without 
endometriosis and DEHP treatment compared to the mice given the SHAM surgery and 
treated with 60 mg/kg DEHP 












































Figure 33. Activation of microglia in the brain of mice with endometriosis. (A) 
Morphological changes in microglia when activated.  Iba-1 immunostaining for microglia in 
the hippocampal region of (B-D) the brain in  mice without endometriosis (B) control (C) 
sham oil (D) sham DEHP.; Iba-1 immunostaining in mice with endometriosis (E-G)  (E) 
vehicle control, (F) 30mg/kg DEHP and (G) 60mg/kg DEHP. Images are at 40X and inset 
images are 10X. 
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Figure 34. Quantification of Iba-1 expression in the brain. (A) One-way ANOVA 
analysis of Iba-1 staining for microglia in the hippocampal region of the brain from mice 
collected at day 32. Iba-1 expression was significantly higher in mice treated with 60 
mg/kg DEHP compared to the control (**p=0.0099). For more accurate statistical 
significance grouping of treatments was done to isolate the effects on Iba-1 staining of 
brains from mice with (B) endometriosis only (^p=0.0556), (C) the effects of 60 mg/kg 
DEHP treatment without endometriosis (*p=0.0167) and (D) the effects of endometriosis 
and DEHP (**p=0.0044) all compared to mice without treatment of DEHP or 
endometriosis. (E) Iba-1 expression is significantly increased between mice with 












































































Figure 35. Activation of microglia in the spinal cord.  Iba-1 staining for microglia in the 
dorsal root region of the spinal column from a (A) control mouse, (B) a mouse without 
endometriosis treated with vehicle control, (C) a mouse without endometriosis treated with 60 
mg/kg DEHP. Iba-1 staining for microglia in the dorsal root region of the spinal column from 




























Figure 36. Quantification of Iba-1 expression in the spinal cord. (A) One-way ANOVA 
analysis of Iba-1 staining for microglia in the dorsal root region of the spinal column from 
mice collected at day 32.  Iba-1 expression was significantly higher in mice treated with 60 










































































DEHP is a chemical that women are continuously exposed to and the effects of such 
exposure on endometriosis are unknown. However, higher levels of DEHP metabolites have 
been measured in urine samples from women with endometriosis compared to women without 
endometriosis.146–148 This suggests that DEHP exposure may contribute to the development and 
establishment of this disease. However DEHP is a phthalate, a group of chemicals known for 
their non-monotonic dose responses. Unlike other toxicants, adverse reactions are not always 
correlated with an increase in dose; effects from phthalates can be seen at low or mid-range 
doses with no effect at high doses.149 Our results showed that endometriotic lesions collected 
from mice treated with 30 mg/kg/day DEHP were significantly larger and were maintained 
longer than lesions collected from mice treated with the vehicle control or 60 mg/kg/day and 
demonstrate that DEHP has an effect on the progression of the disease but appears to be acting in 
a non-linear dose response manner. The increased volume of lesions in the 30 mg/kg/day DEHP 
treatment group can be explained by the observed increase in proliferation in the lesions. We also 
collected many more lesions at day 32 from mice treated with 30 mg/kg DEHP as compared to 
the vehicle control. Previous studies showed that endometrial cells treated with DEHP have a 
higher survival rate under conditions that are traditionally lethal, such as treatment with 
hydrogen peroxide or hypoxia.150 This could be a factor contributing to the increased number of 
lesions in the DEHP treatment groups as the DEHP may promote both proliferation and survival 
of lesions and make them less susceptible to apoptosis and cellular breakdown in the peritoneal 
cavity. DEHP has also been reported to act on peritoneal macrophages to cause decreased 
phagocytosis behavior.151 Macrophages that would normally locate and attack endometrial cells 
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to clear lesions are no longer working at the same capacity thus allowing for lesions to continue 
to grow and progress in our mice at day 32 post- transplantation.   
Our studies also determined that there was decreased burrowing behavior in mice with 
endometriosis confirming that the mice with endometriosis were experiencing pain and 
discomfort. The mice that received the sham surgery and treated with vehicle control or 60 
mg/kg/day DEHP had similar burrowing behavior to the untreated control mice confirming that 
the DEHP did not cause chronic pain or discomfort in the mice. Confirmation of this sensitive 
pain response in the mice with endometriotic lesions indicated to us that there may be 
neuroinflammatory signals being communicated to the brain activating the immune cells there. 
In fact, we did observe an increase in the numbers of activated microglia in both the brain and 
spinal cord of mice with endometriosis compared to the control and sham mice treated with 
vehicle control. We also saw a heightened number of Iba-1 expressing cells in the sham mice 
treated with 60 mg/kg DEHP demonstrating that the DEHP treatment is also capable of acting on 
the brain to promote neuroinflammation even in the absence of endometriotic lesions. This is 
also shown by increased Iba-1 expression in the mice with endometriosis and treated with DEHP 
compared to mice with endometriosis treated with vehicle control, DEHP is capable of 
exacerbating the neuroinflammation response. The microglia are the resident immune cells in the 
brain and spinal cord. During their resting or quiescent state, they have long outstretched 
processes that are constantly monitoring the brain. These cells will become activated or 
hypertrophic in their early response to an immune stimulus or trauma and then subsequently 
become amoeboid as they become motile and travel throughout the brain to respond to the 




A possible reason for the increased expression of Iba-1 in the brain and spinal cord could 
be linked with central sensitization. There are published studies showing that women with 
endometriosis experience central sensitization, a condition involving changes in the central 
nervous system due to chronic inflammation and pain that results in heightened pain response 
from stimuli that would normally be considered inconsequential.152 Inflammation in the 
peritoneal cavity, such as an intraperitoneal injection of lipopolysaccharide or tumor necrosis 
factor alpha, or changes in the gut microbiome and endometriosis are all capable of triggering the 
activation of neuroinflammation in the brain.99,103,113,130,153–155 Central sensitization is triggered 
by endometriotic lesions in two ways.  The lesions secrete pro-inflammatory cytokines that can 
act directly on the brain through the blood-brain barrier to activate microglia and to sensitize 
nerve fibers in the peritoneum that communicate through afferents in the peritoneum to the spinal 
cord and brain.99–101,130,156 These signals activate microglia in the brain, and when activated, the 
microglia secrete more pro-inflammatory signals such as reactive oxygen species and other 
cytotoxins that  promote neuroflammation and can act in an autocrine or paracrine manner in the 
central nervous system.103,112,113,124 These signals act in a continuous feedback loop increasing 
the activation and inflammation causing permanent changes in the brain. This results in 
hyperexcitability in the brain and spinal cord that leads to chronic pain in areas outside of the 
peritoneal cavity even after  the endometriotic lesions are removed.130,156,157 Women with 
confirmed endometriosis have been tested for pain responses to stimuli such as saline injection in 
the muscle, and have been shown to display a greater pain response and have more areas in the 
body where the pain is felt compared to women without endometriosis.158,159 Studies have also 
shown that mice with endometriosis can develop central sensitization and that it manifests as 
increased depression and anxiety behavior in mice with endometriosis.130,153 
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This study has provided new insight into the effects of DEHP on neuroinflammation and 
disease progression of endometriosis. Proliferation in endometriotic lesions was increased by 
DEHP exposure resulting in more and larger lesions in mice treated with 30 mg/kg/day. Our 
results confirm an association between DEHP exposure and endometriosis. Endometriosis is a 
painful disease that decreases burrowing behavior in mice, confirmed by the fact that a sham 
surgery by itself did not alter burrowing. Neuroinflammation was triggered by both daily 
exposure to DEHP and endometriosis since activated microglia were found in both mice with 
endometriosis but no DEHP as well as in mice exposed to DEHP but without endometriosis. This 
mouse model of endometriosis can be utilized to study the effects of other endocrine disrupting 
chemicals on endometriosis as well as their contribution to central sensitization.  
 















CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
 
Endometriosis is a very complex disease with many factors contributing to its onset and 
progression. Sampson’s theory of retrograde menstruation is an accepted explanation for the 
cause of this disease, however the reasons for the disparity between 90% of women experiencing 
retrograde menstruation and only 10% of women experiencing endometriosis are unknown. We 
believe that dysregulation of the immune system is a large contributing factor to the 
establishment of endometriosis, and that several factors including alterations in the hormone 
profile of the patient, genetic alterations, or environmental exposure to endocrine disrupting 
chemicals such as DEHP may lead to a more pro-inflammatory environment that promotes 
disease progression. The goal of this study was to validate our mouse model of endometriosis 
and use this model to determine whether DEHP has an effect on the incidence and progression of 
endometriosis and whether establishment of endometriosis leads to proinflammatory effects on 
the brain and spinal cord. We confirmed that the lesions collected from our mice were 
histologically similar to lesions found in women through immunostaining for several cell-
specific markers. We determined that the endometriotic lesions in mice contained endometrial 
stromal cells, glands, a robust blood supply and active proliferation. Using our validated mouse 
model of endometriosis we made the following significant findings in our studies: 1) C57BL/6 
mice are a superior mouse strain for use in  a mouse model of endometriosis and supplementing 
ovariectomized C57BL/6 mice with estradiol valerate results in a higher incidence of 
endometriotic lesions; 2) treatment of  mice with 30 mg/kg or 60 mg/kg/day DEHP resulted in 
increased incidence and size of lesions and increased cell proliferation in endometriotic lesions; 
3) mice with endometriotic lesions showed signs of  discomfort or pain in association with 
induction of  endometriosis and the presence of endometriotic lesions or treatment with DEHP 
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resulted in increased numbers of  activated microglia in the hippocampus of the brain. 
  We discovered that C57BL/6 mice develop more endometriotic lesions than the CD-1 
mice and that lesions in the C57BL/6 mice were larger and contained more glands. Due to the 
striking differences in disease presentation between C57BL/6 and CD-1 mice it would be 
interesting, in future studies, to study other inbred strains and determine if C57BL/6 mice are 
more genetically prone to develop endometriosis or is the fact that they are an inbred line the 
cause of the increased incidence and size of lesions.  We also determined that estradiol valerate 
is a better estrogen supplement when using ovariectomized mice in a transplantation model of 
endometriosis than 17-β estradiol, probably due to its increased stability.  
 Our studies testing the effects of DEHP on endometriosis showed that the mice treated 
with either 30 mg/kg/day or 60 mg/kg/day DEHP had a greater number of lesions with higher 
rates of cell proliferation at day 32 post-transplantation than the vehicle controls. The mice 
treated with 30 mg/kg/day DEHP also had significantly larger lesions than the vehicle control.  
This leads us to think that it would be interesting to continue to monitor the size and number of 
lesions collected from treated mice at later time points such as a 6, 12 or 18 months post-
transplantation to see if DEHP exposure increases the long term lifespan of the lesions.  
We also wanted to assess the effects of endometriosis on development of visceral pain or 
discomfort in our mouse model and used a behavioral assay that has been validated for 
measurement of pain. Burrowing is an innate behavior in mice that has been discovered to be a 
sensitive marker for pain response. By using this assay we determined, from decreased 
burrowing activity, that the mice with endometriosis were experiencing pain or discomfort. 
Examination of the hippocampus region of the brain revealed that mice with endometriosis had 
significantly more hypertrophic microglia in this region, which is important for memory and 
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learning as well as an important location for signaling of persistent pain. The demonstration that  
mice with endometriotic lesions have increased numbers of chronically activated microglia 
suggests that humans with endometriosis could potentially also have chronically activated 
microglia contributing to the development of chronic pelvic pain and perhaps injuring their 
brains for many years while suffering from this disease. We also saw that treating mice with 
DEHP was enough to elicit the same increased activation of microglia without the presence of 
endometriotic lesions. This could indicate that constant exposure to phthalates can trigger 
neuroinflammation and could lead to neurodegenerative disorders even in the absence of a 
chronic disease. Noting that this model is able to detect pain/discomfort in mice with 
endometriosis and that the mice with endometriotic lesions displayed decreased burrowing 
behavior, it would be interesting to determine whether antagonists of microglia activation, such 
as the A2AR antagonist ZM241385, could inhibit this activation or reverse it leading to a 
decrease in neuroinflammation and the associated visceral pain. Such a treatment could provide 
potential protection from neurodegeneration caused by chronically activated microglia in women 
suffering from endometriosis. We would also like to monitor burrowing behavior in mice bearing 
endometriosis for a longer period of time to determine how long the mice will continue to 
present with pain, or alternatively dose mice continuously with an analgesic such as 
buprenorphine to determine if the reducing pain will rescue burrowing behavior.  
 In conclusion, we have determined that repeated exposure to DEHP increases 
proliferation in endometriotic lesions resulting in increased size and number of lesions in the 
peritoneum. DEHP has also been shown in the literature to increase peritoneal macrophage 
population and decrease phagocytic behavior in macrophages.151 These findings together provide 
a possible explanation for the link between women with endometriosis and increased DEHP 
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levels. We also discovered that DEHP exposure alone has the capability to activate microglia in 
the brain and spinal column. This has previously been thought to occur in response to harsher 
trauma or inflammation. We have determined that the presence of endometriotic lesions and the 
cytokines they produce cause inflammation that results in a pain response in mice and triggers 
inflammation and activation in the brain (Figure 37). Our research studies shed light on the 
potential effects that phthalate exposure on women with endometriosis and the greater risk of 








































Figure 37. Model of the effect of DEHP exposure on endometriosis. DEHP increases 
proliferation in endometriostic lesions. Peritoneal macrophage populations and 
inflammatory cytokines are increased with DEHP exposure and DEHP decreases 
phagocytic capabilities of macrophages in the peritoneal cavity.151 Activation of microglia 
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APPENDIX A: MATERIALS AND ANTIBODIES 
 
 
Item Company Catalog # 
Formalin  Sigma Aldrich  HT501128-4L 
Hydrogen Peroxide 30% Sigma Aldrich H1009 
Histoplast HE  Thermo Fisher 8330 
Clearmount Mounting Medium American Master Tech  MMC016 
DAB Peroxidase Substrate Kit with 
Nickle  
Vector Laboratories SK-4100 
Biotinylated Goat Anti-Rabbit IgG 
Antibody  
Vector Laboratories BA-1000 
Vectastain Elite ABC Standard Kit Vector Laboratories PK-6100 
Super Frost Plus Microscope Slides Fisher Scientific 12-550-15 
RNAlater Ambion AM7021 
DAKO Target Retrieval Solution pH=9 DAKO S236784 
Normal Horse Serum Blocking Solution Vector Laboratories S-2000 
Rabbit IgG Sigma Aldrich 15006 
Bis(2-ethylhexyl) phthalate (DEHP)  Sigma Aldrich 36735 
Eosin Y Solution Sigma Aldrich HT110132 
Normal Goat Serum Blocking Solution Vector Laboratories S-1000 
AutoClip System  Fine Science Tools 12020-00 
Modified Mayer's Hematoxylin American Master Tech HXMMHLT 
95 
 
Bovine Serum Albumin Fisher Scientific BP1600-100 
Mouse IgG (Control Antibody) Vector Laboratories 1-2000 
Biotinylated Horse Anti-Mouse IgG 
antibody  
Vector Laboratories  BA-2000 
Pregnant Mare Serum Gonadatropin 
(PMSG)  
National Hormone & Peptide 
Program 
N/A 
Beta-Estradiol Sigma Aldrich  E8875 
Estradiol Valerate Sigma Aldrich E1631 
Goat Anti-Rat IgG Antibody Vector Laboratories PI-9400 
Methanol  Fisher Scientific A946-4 
Low Cost Cauterizer Kit Fine Scientific Tools 18010-00 
5-0 Redigut Plain 27” MFS-2  Sutures Ultimate Dental GP820-BRC 
Ketamine, Xylazine, Buprenorphine Provided by UIUC DAR 
office  
 
Corn Oil  Sigma Aldrich C8267 

























 (ab15580)  
1:400 Normal Goat Anti-Rabbit IgG 
Rabbit Polyclonal 
to CD31 (PECAM) 
Abcam  
(ab28364) 





1:200 Normal Horse Anti-Mouse IgG 



































APPENDIX B: TISSUE PROCESSING & HISTOLOGY 
 
Sample Processing 
 Harvested tissues were placed in formalin for 24 hours. The tissues were then transferred to 70% 
ethanol for storage until processing. Samples were then processed in at Tissue-Tek tissue 
processor using the following schedule:  
Solution Time Temperature  
70% EtOH   
 
30 minutes 35⁰ C 
80% EtOH   30 minutes 35⁰ C 
90% EtOH   45 minutes 35⁰ C 
100% EtOH   45 minutes 35⁰ C 
100% EtOH   45 minutes 35⁰ C 
100% EtOH   45 minutes 35⁰ C 
Xylene 45 minutes 35⁰ C 
Xylene 30 minutes  35⁰ C 
Xylene 45 minutes 35⁰ C 
Paraffin 60 minutes 60⁰ C 
Paraffin 60 minutes  60⁰ C 
 
The spinal column was removed from the body and placed in 10% neutral buffered formalin for 
48hrs.  Spines were then transferred into 70% ethanol until they were decalcified using 5% 
EDTA for 2 days. They were then rinsed with water and placed into 70% ethanol. The spines 
were cut into 1 cm pieces and then processed using the same schedule before embedding in 
paraffin.  
Histochemistry 
Paraffin embedded tissue were sectioned at 5µm and adhered to treated glass slides.  
Deparaffinization was performed with three 5 minute washes of xylene. Tissue sections were 
rehydrated by placing them in a series of ethanol washes with a reduction in ethanol 
concentration (100% x2 minutes, 90%, 70% 1 minute each) followed by 1 minute of deinonized 
water. The tissue sections were then stained with Modified Mayer's Hematoxylin (1 minute) and 
Eosin Y Solution (1 minute) to allow examinations of the morphology of the tissues.  Tissue 
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sections were dehydrated with a series of ethanol washes (70%, 90%, 100% x2 1 minute each). 
Clearing was done with three washes for 1 minute each with xylene. Slides were then mounted 
with Clearmount.   
Immunohistochemistry  
Paraffin embedded tissues were sectioned at 5µm and adhered to treated glass slides.  
Deparaffinization was performed on tissue sections with xylene for three 5 minute washes.  
Tissue sections were rehydrated by placing them in a series of ethanol washes with a reduction in 
ethanol concentration (100% x2 minutes, 90%, 70% 1 minute each) followed by 1 minute of 
water.  Antigen retrieval of tissue sections was carried out by placing slides in Dako target 
retrieval solution for 30 minutes in a water bath at 99.9⁰ F. After this the tissue sections were   
removed from the water bath and allowed to cool to room temperature in the Dako solution for 
20 minutes. Slides were then washed in 1X PBST (Phosphate Buffered Saline\Tween 20) for 5 
minutes with slight agitation before blocking endogenous peroxidase activity with a 3% 
hydrogen peroxide and methanol solution for 30 minutes. This was followed by three more 5 
minute washes with PBST with slight agitation. The tissue sections were then blocked with 10% 
normal serum in 1% BSA/PBST (Bovine Serum Albumin / Phosphate Buffered Saline/Tween 
20) for 60 minutes. Primary antibody at the dilution described in the table below for the 
corresponding antibody (Appendix A) was applied and incubated at 4⁰C overnight. This was 
followed by three PBST washes for 5 minutes with slight agitation. Tissue sections were then 
incubated with the corresponding secondary antibody at a dilution of 1:200 for 1 hour at room 
temperature. Slides were washed three times for 5 minutes each with slight agitation. ABC 
complex was applied to the slides and incubated at room temperature for 30 minutes. This was 
followed by three more 5 minute washes in PBST with slight agitation. DAB was used as a 
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chromogen and was applied to slides for various times based on the particular antibody being 
utilized (Appendix A).  Tissue sections were counterstained in hematoxylin for 30 seconds, then 
rinsed in tap water. Dehydration was performed by putting slides through a sequence of 
increasing concentrations of ethanol (70%, 90%, 100% x2 1 minute each). Clearing was done 
with three washes in xylene for 1 minute each. Slides were then mounted with Clearmount.   
Iba-1 Immunohistochemistry  
Slides used for Iba-1 immunostaining underwent antigen retrieval for only 9 minutes. 
There was also no quenching of endogenous peroxidase. The Iba-1 primary antibody was diluted 














































































Quantification with FIJI on endometriotic lesion. (A) Original image of lesion stained 
with PECAM, (B) fat and artifact cut out of the image. (C) Probability maps of “blue” 
unstained area and, (D) “brown” stained area. (E) Adjusted threshold image to measure 
unstained area and (F) stained area. Area of the stained area over the unstained area to 
result in percent positive stained area.  
